TVTX: Guggenheim Raises PT
Guggenheim analyst Vamil Divan raises price target on Travere Therapeutics to $65 and keeps Buy rating ahead of Q2 earnings
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.